125 related articles for article (PubMed ID: 498169)
1. Pharmacology of intravenous melphalan in patients with multiple myeloma.
Brox L; Birkett L; Belch A
Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169
[No Abstract] [Full Text] [Related]
2. Intermittent melphalan therapy in multiple myeloma.
Hoogstraten B; Costa J; Cuttner J; Forcier J; Leone LA; Harley JB; Glidewell OJ
JAMA; 1969 Jul; 209(2):251-3. PubMed ID: 5819231
[No Abstract] [Full Text] [Related]
3. [Treatment of multiple myeloma with melphalan: 35 personal cases].
Dryll A; Ryckewaert A; Kahn MF; Hayat M; de Seze S
Sem Hop; 1970 Jan; 46(5):289-98. PubMed ID: 4327260
[No Abstract] [Full Text] [Related]
4. Multiple myeloma--intermittent combination chemotherapy compared to continuous therapy.
George RP; Poth JL; Gordon D; Schrier SL
Cancer; 1972 Jun; 29(6):1665-70. PubMed ID: 4113171
[No Abstract] [Full Text] [Related]
5. Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents.
Ringborg U; Lewensohn R
Acta Med Scand; 1978; 203(4):276-8. PubMed ID: 645439
[TBL] [Abstract][Full Text] [Related]
6. Melphalan in multiple myeloma.
Hoogstraten B; Sheehe PR; Cuttner J; Cooper T; Kyle RA; Oberfield RA; Townsend SR; Harley JB; Hayes DM; Costa G; Holland JF
Blood; 1967 Jul; 30(1):74-83. PubMed ID: 6028709
[No Abstract] [Full Text] [Related]
7. The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.
Loos U; Musch E; Engel M; Hartlapp JH; Hügl E; Dengler HJ
Eur J Clin Pharmacol; 1988; 35(2):187-93. PubMed ID: 3191937
[TBL] [Abstract][Full Text] [Related]
8. [Use of intravenous melphalan in the treatment of Kahler's disease].
Balmes A; Dauverchain J; Othoniel J; Mandin A; Chavanette F
Presse Med (1893); 1971 May; 7(23):1072. PubMed ID: 5577947
[No Abstract] [Full Text] [Related]
9. Short course intermediate dose intravenous melphalan therapy in myeloma--relation to early emergence of drug resistance (phase II study).
Sviland L; Leggat H; Harris AL; Bird G; Proctor SJ
Acta Haematol; 1987; 78(4):233-8. PubMed ID: 3122488
[TBL] [Abstract][Full Text] [Related]
10. Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment.
Petrucci MT; Avvisati G; Tribalto M; Cantonetti M; Giovangrossi P; Mandelli F
Eur J Haematol; 1989 Mar; 42(3):233-7. PubMed ID: 2924885
[TBL] [Abstract][Full Text] [Related]
11. Single-dose intravenous melphalan in advanced multiple myeloma.
Bäck H; Lindblad R; Rödjer S; Westin J
Acta Haematol; 1990; 83(4):183-6. PubMed ID: 2115714
[TBL] [Abstract][Full Text] [Related]
12. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
McElwain TJ; Powles RL
Lancet; 1983 Oct; 2(8354):822-4. PubMed ID: 6137651
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
[TBL] [Abstract][Full Text] [Related]
14. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
Alexanian R; Haut A; Khan AU; Lane M; McKelvey EM; Migliore PJ; Stuckey WJ; Wilson HE
JAMA; 1969 Jun; 208(9):1680-5. PubMed ID: 5818682
[No Abstract] [Full Text] [Related]
15. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
Palumbo A; Falco P; Falcone A; Benevolo G; Canepa L; Gay F; Larocca A; Magarotto V; Gozzetti A; Luraschi A; Morabito F; Nozza A; Knight RD; Zeldis JB; Boccadoro M; Petrucci MT
Clin Lymphoma Myeloma; 2009 Apr; 9(2):145-50. PubMed ID: 19406725
[TBL] [Abstract][Full Text] [Related]
16. Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
Acta Oncol; 1990; 29(6):727-31. PubMed ID: 2223143
[TBL] [Abstract][Full Text] [Related]
17. Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher risk multiple myeloma patients.
Petrucci MT; La Verde G; Ribersani M; Avvisati G; Mandelli F
Leuk Lymphoma; 2000 Sep; 39(1-2):131-8. PubMed ID: 10975391
[TBL] [Abstract][Full Text] [Related]
18. Stem cell mobilization in heavily pretreated multiple myeloma patients with prior high dose melphalan and auto-SCT.
Khaled Y; Al-Hazzouri A; Mizrachi A; Reynolds R; Reddy V; Solh M
Bone Marrow Transplant; 2013 Feb; 48(2):310-1. PubMed ID: 22773127
[No Abstract] [Full Text] [Related]
19. Alkeran and multiple myeloma.
Med Lett Drugs Ther; 1966 Apr; 8(8):32. PubMed ID: 5913764
[No Abstract] [Full Text] [Related]
20. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
